H209 CDX Model

The H209 cell line originates from human small cell lung cancer (SCLC), a type of lung cancer characterized by its aggressive growth and tendency for early metastasis. H209 offers an indispensable model for researchers aiming to unravel the complexities of SCLC biology, its underlying molecular pathways, and potential therapeutic interventions. This cell line mirrors many of the molecular characteristics and genetic mutations commonly associated with SCLC, further solidifying its position as a representative tool for preclinical research. The behavior of H209 in both in vitro and in vivo settings provides insights into SCLC’s rapid growth, neuroendocrine characteristics, potential for metastatic spread, and inherent responsiveness or resistance to chemotherapeutic agents. H209 is widely used by researchers seeking to delve deeper into the molecular drivers of SCLC, as well as to test and refine emerging therapeutic strategies, especially in the realm of targeted therapies and immunotherapies.

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.